Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

UPDATE: Assertio Therapeutics Q3 Adj. EPS $0.22 Beats $0.07 Estimate

Assertio Therapeutics (NASDAQ:ASRT) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.07 by 214.29 percent. This is a 175 percent increase over earnings of $0.08 per share
byBenzinga Newsdesk
November 8, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Assertio Therapeutics (NASDAQ:ASRT) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.07 by 214.29 percent. This is a 175 percent increase over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $34.21 million which beat the analyst consensus estimate of $31.33 million by 9.20 percent. This is a 34.31 percent increase over sales of $25.47 million the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Immunic’s Earnings Outlook

By Benzinga Insights
November 2, 2:45 PM
Immunic (NASDAQ:IMUX) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Immunic will report an earnings per share (EPS) of $-0.66.

IMUX